MX2023007058A - Metodos de tratamiento del cancer de mama con derivados de tetrahidronaftaleno como degradadores del receptor de estrogenos. - Google Patents

Metodos de tratamiento del cancer de mama con derivados de tetrahidronaftaleno como degradadores del receptor de estrogenos.

Info

Publication number
MX2023007058A
MX2023007058A MX2023007058A MX2023007058A MX2023007058A MX 2023007058 A MX2023007058 A MX 2023007058A MX 2023007058 A MX2023007058 A MX 2023007058A MX 2023007058 A MX2023007058 A MX 2023007058A MX 2023007058 A MX2023007058 A MX 2023007058A
Authority
MX
Mexico
Prior art keywords
sup
breast cancer
methods
estrogen receptor
treating breast
Prior art date
Application number
MX2023007058A
Other languages
English (en)
Spanish (es)
Inventor
Yimin Qian
John Flanagan
Andrew P Crew
Jing Wang
Xin Chen
Sheryl Maxine Gough
Iii Royal J Haskell
Marcia Dougan Moore
Ian Charles Anthony Taylor
Original Assignee
Arvinas Operations Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arvinas Operations Inc filed Critical Arvinas Operations Inc
Publication of MX2023007058A publication Critical patent/MX2023007058A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MX2023007058A 2020-12-14 2021-12-13 Metodos de tratamiento del cancer de mama con derivados de tetrahidronaftaleno como degradadores del receptor de estrogenos. MX2023007058A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063125371P 2020-12-14 2020-12-14
PCT/US2021/063130 WO2022132652A1 (en) 2020-12-14 2021-12-13 Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders

Publications (1)

Publication Number Publication Date
MX2023007058A true MX2023007058A (es) 2023-06-23

Family

ID=79288002

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023007058A MX2023007058A (es) 2020-12-14 2021-12-13 Metodos de tratamiento del cancer de mama con derivados de tetrahidronaftaleno como degradadores del receptor de estrogenos.

Country Status (11)

Country Link
US (1) US20220193072A1 (cg-RX-API-DMAC7.html)
EP (1) EP4259137A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024501471A (cg-RX-API-DMAC7.html)
KR (1) KR20230121801A (cg-RX-API-DMAC7.html)
CN (1) CN116744925A (cg-RX-API-DMAC7.html)
AU (1) AU2021401580A1 (cg-RX-API-DMAC7.html)
CA (1) CA3202592A1 (cg-RX-API-DMAC7.html)
IL (1) IL303143A (cg-RX-API-DMAC7.html)
MX (1) MX2023007058A (cg-RX-API-DMAC7.html)
TW (1) TW202237117A (cg-RX-API-DMAC7.html)
WO (1) WO2022132652A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL266842B (en) 2016-12-01 2022-09-01 Arvinas Operations Inc History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists
WO2021041348A1 (en) 2019-08-26 2021-03-04 Arvinas Operations, Inc. Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
CN115746058A (zh) * 2021-09-03 2023-03-07 南京知和医药科技有限公司 一种多环化合物在制备抗肿瘤药物方面的用途
EP4554948A1 (en) * 2022-07-12 2025-05-21 Regents of the University of Michigan Tetrahydronaphthalene derivatives as estrogen receptor degraders
WO2024049926A1 (en) * 2022-08-31 2024-03-07 Arvinas Operations, Inc. Dosage regimens of estrogen receptor degraders
WO2024196053A1 (ko) * 2023-03-17 2024-09-26 재단법인 대구경북첨단의료산업진흥재단 에스트로겐-연관 수용체 감마 억제제 및 항암제의 병용요법용 조성물
TW202440096A (zh) * 2023-03-24 2024-10-16 美商亞文納營運公司 雌激素受體降解劑之給藥方案
JP2026518466A (ja) * 2023-06-02 2026-06-08 アルビナス・オペレーションズ・インコーポレイテッド エストロゲン受容体分解剤とakt阻害剤との組み合わせ
JP2026519559A (ja) 2023-06-02 2026-06-16 ファイザー・インク エストロゲン受容体分解薬およびcdk4阻害剤の組合せ
WO2025122502A1 (en) * 2023-12-04 2025-06-12 Foundation Medicine, Inc. Methods for treating hr-positive her2-negative breast cancer
CN121646481A (zh) * 2024-07-04 2026-03-10 海创药业股份有限公司 一种雌激素受体降解剂和akt抑制剂联合用药物及其用途
WO2026128391A1 (en) 2024-12-09 2026-06-18 Arvinas Operations, Inc. Combinations of vepdegestrant and cdk4/6 inhibitors for treating esr1-mutant breast cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
SG11201607334YA (en) * 2014-03-13 2016-10-28 Hoffmann La Roche Therapeutic combinations with estrogen receptor modulators
MX384605B (es) * 2015-04-29 2025-03-14 Radius Pharmaceuticals Inc Combinación de palbociclib y rad1901 para usarse en el tratamiento de cáncer de mama en un sujeto con cáncer positivo a receptor de estrógeno.
IL266842B (en) 2016-12-01 2022-09-01 Arvinas Operations Inc History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists
CA3095912A1 (en) * 2018-04-13 2019-10-17 Arvinas Operations, Inc. Cereblon ligands and bifunctional compounds comprising the same
MX2021006411A (es) * 2018-12-06 2021-07-21 Radius Pharmaceuticals Inc Metodos para el tratamiento del cancer resistente a inhibidores de cinasa 4 y cinasa 6 dependiente de ciclina (cdk4/6).
WO2021041348A1 (en) * 2019-08-26 2021-03-04 Arvinas Operations, Inc. Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders

Also Published As

Publication number Publication date
IL303143A (en) 2023-07-01
AU2021401580A1 (en) 2023-06-22
TW202237117A (zh) 2022-10-01
CA3202592A1 (en) 2022-06-23
US20220193072A1 (en) 2022-06-23
CN116744925A (zh) 2023-09-12
WO2022132652A1 (en) 2022-06-23
JP2024501471A (ja) 2024-01-12
KR20230121801A (ko) 2023-08-21
EP4259137A1 (en) 2023-10-18

Similar Documents

Publication Publication Date Title
MX2022002415A (es) Metodos de tratamiento del cancer de mama con derivados de tetrahidronaftaleno como degradadores del receptor de estrogenos.
MX2022014192A (es) Metodos para tratar el cancer de prostata.
MX2023006883A (es) Metodos para tratar el cancer de prostata.
MX2022008066A (es) Compuestos triciclicos sustituidos.
MX2025000642A (es) Compuestos macrociclicos para el tratamiento de cancer
PH12023550130A1 (en) Tetrahydropyrazolo-pyrazinyl-dihydroimidazolone or tetrahydropyrazolo-pyridinyl-dihydroimidazolone compounds and methods of using same
MX2025001995A (es) Compuesto heterociclico, procedimiento para prepararlo y uso farmaceutico del mismo
MX2022013054A (es) Derivados de imidazolidinona y uso medico de los mismos.
MX2020000268A (es) Agonista de fxr.
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
MX2010001189A (es) Derivados de naftiridina como modulares del canal de potasio.
MX2025007797A (es) Derivado de tetrahidrotiofeno y uso de este en medicina
MX2024003738A (es) Formas solidas, composiciones farmaceuticas y preparacion de compuestos de eter macrociclico heteroaromatico.
MX2023001671A (es) Procedimiento y compuesto para su uso en el tratamiento y/o prevención de la netosis.
MX2009009574A (es) Tratamiento de melanoma.
ZA202401684B (en) Novel parp7 inhibitor and use thereof
MX2022016554A (es) Métodos de tratamiento del cáncer mediante derivados heteroaril-bifenil-amida.
MX2023013715A (es) Regímenes de dosis de ecubectedina.
MX2024002409A (es) Terapias contra el cancer.
GEAP202516737A (en) Compounds for treating cancer
MX2020013076A (es) Compuestos de acido ascorbico y quinona en combinacion con un agente antiparasitario para el tratamiento de una enfermedad parasitaria.
RU2015114967A (ru) Производные ингенола, применяемые для лечения рака
MX2025010256A (es) Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno
MX2025004409A (es) Metodos de tratamiento del cancer usando derivados de isoquinolina o 6-aza-quinolina
MX2023009962A (es) Composicion farmaceutica combinada que contiene inhibidor de cdk4/6 y su uso.